secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206382
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports Q1 net loss $13.2M; cash runway extended to 2030 after $162M offering
--------------------------------------------------------------------------------

- Net loss of $13.2M in Q1 2026 vs $10.3M YoY; R&D expenses $9.9M, G&A $5.0M.
- Cash, equivalents and marketable securities $171.8M at March 31; April offering net ~$162M.
- FDA alignment on Phase 3 plan for Haduvio in IPF-related chronic cough; first Phase 3 starts Q2 2026.
- Phase 2b in refractory chronic cough starts Q2 2026; Phase 2b in non-IPF ILD cough starts H2 2026.
- European patent granted for nalbuphine ER in IPF cough, expiration 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/0001193125-26-206382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/trvi-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer